Inovio pharmaceuticals, inc. (INO)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Revenue from Contract with Customer, Excluding Assessed Tax

1,327

279

866

135

2,829

2,502

2,000

24,448

1,529

8,787

2,644

20,412

10,376

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue under collaborative research and development arrangements

-

-

-

-

-

-

-

-

-

-

-

-

-

476

2,327

1,889

1,796

1,820

16,475

4,335

4,245

1,758

1,114

3,107

1,435

822

8,388

14

14

14

22

20

24

-

-

-

-

-

-

Revenue under collaborative research and development arrangements with affiliated entities

-

-

-

-

-

-

-

-

-

-

-

-

-

189

574

499

137

375

125

166

112

112

112

137

116

106

106

106

106

142

222

106

106

-

-

-

-

-

-

Revenue under collaborative research and development arrangements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

132

183

131

120

39

55

Revenue under collaborative research and development arrangements with affiliated entities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

93

118

Revenue under collaborative research and development arrangements

-

-

-

-

-

-

-

-

-

-

-

-

-

476

2,327

1,889

1,796

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grants and miscellaneous revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

7,735

9,410

3,814

6,176

3,739

7,583

784

808

586

612

556

804

811

991

665

1,334

977

609

308

1,562

1,499

2,454

2,288

2,985

1,075

960

Grants and miscellaneous revenue from affiliated entity

-

-

-

-

-

-

-

-

-

-

-

-

-

112

227

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Miscellaneous revenue from affiliated entity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

67

-

Total revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

8,513

12,540

6,203

8,110

5,935

24,183

5,286

5,166

2,457

1,840

3,801

2,357

1,739

9,486

785

1,455

1,134

854

436

1,693

1,632

2,637

2,419

3,105

1,276

1,134

Operating expenses:
Research and development

19,111

22,003

19,137

22,486

24,389

26,365

21,851

22,462

24,577

24,641

25,510

23,878

24,542

23,911

26,980

19,630

18,189

15,601

16,075

16,688

9,426

9,244

7,017

9,607

8,225

6,404

5,438

4,411

5,115

4,442

4,972

4,527

4,042

4,158

6,987

4,463

4,421

2,951

3,083

General and administrative

7,448

8,696

5,681

5,850

6,975

5,636

6,791

7,189

9,698

8,033

6,319

6,169

7,767

6,965

5,755

5,799

5,371

4,860

4,377

4,718

4,107

4,224

3,153

4,347

4,132

4,339

3,282

3,046

2,974

2,919

2,674

2,696

2,488

3,253

2,323

3,092

3,319

2,881

3,027

Gain (Loss) on Disposition of Intangible Assets

-

-

-

-

-

-

-

-

-

1,000

0

0

0

0

0

1,000

0

0

0

1,000

0

-

-

-

-

1,000

0

1,000

0

0

500

0

651

0

337

0

250

-

-

Total operating expenses

26,559

30,700

24,818

28,336

31,364

32,001

28,643

29,651

34,275

31,675

31,830

30,047

32,310

30,877

32,735

24,430

23,560

20,461

20,452

20,406

13,534

13,468

10,171

13,954

12,357

9,743

8,721

6,457

8,089

7,361

7,146

7,223

5,879

7,412

8,974

7,556

7,491

5,833

6,110

Loss from operations

-25,232

-30,421

-23,951

-28,200

-28,535

-29,499

-26,642

-5,203

-32,746

-22,887

-29,185

-9,635

-21,933

-22,363

-20,195

-18,226

-15,450

-14,526

3,730

-15,120

-8,367

-11,011

-8,331

-10,152

-10,000

-8,003

765

-5,672

-6,634

-6,227

-6,291

-6,787

-4,186

-5,779

-6,336

-5,136

-4,385

-4,556

-4,975

Other income (expense):
Interest income

416

587

637

755

625

-

565

518

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

2,803

2,668

2,428

2,194

656

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest and other income (expense), net

-

-

-

-

-

-

-

-

312

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14

13

Interest and other income, net

-

-

-

-

-

-169

-

-

-

509

463

300

340

191

391

341

333

-194

214

146

138

113

97

68

52

8

46

37

39

56

37

41

31

18

5

7

1

-

-

Change in fair value of common stock warrants

-

-

-

-

-

0

228

259

-127

579

423

-312

116

644

2

-113

-406

-290

518

-49

-1

143

-113

824

-505

-6,052

-34,952

-3,199

-1,427

3,049

-1,113

3,594

-3,548

1,113

346

4,898

2,331

-

-

Change in fair value of derivative liability

-13,221

-4,315

2,551

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain (loss) on investment in affiliated entities

13,181

-1,681

-485

-173

-750

-3,293

1,017

-2,092

2,380

292

-5,835

169

-1,608

-4,706

-958

-705

7,480

-3,249

-659

8,861

-2,352

3,342

1,168

-1,458

-376

-1,419

3,248

-2,032

-836

2,449

736

-992

-561

-840

1,427

-2,607

-370

2,604

-3,327

Other income (expense), net

-425

263

140

127

-35

-

-184

-121

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

522

676

Net loss before income tax benefit/(provision for income tax)

-33,135

-38,235

-23,536

-29,685

-29,351

-32,962

-25,015

-6,639

-30,181

-

-

-

-

-

-

-

-

-18,260

3,805

-6,162

-10,582

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax benefit/(provision for income taxes)

0

-87

0

-106

-62

0

0

0

2,169

-

-

-

-

-

-

-

-

-308

-1,789

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

-33,135

-38,147

-23,536

-29,579

-29,288

-32,962

-25,015

-6,639

-32,350

-21,506

-34,134

-9,479

-23,085

-

-

-

-

-17,952

5,594

-6,162

-10,582

-7,412

-7,179

-10,717

-10,830

-15,467

-30,890

-10,866

-8,858

-671

-6,632

-4,144

-8,264

-5,488

-4,556

-2,837

-2,422

-1,414

-7,613

Net loss attributable to non-controlling interest

-594

-485

-445

-191

-69

0

0

0

0

-

-

-

-

-

-

-

-

0

0

85

-1

-1

-1

-6

-9

-13

-13

-14

-14

-12

-10

-11

-9

-11

-14

-15

-9

-4

2

Net loss attributable to non-controlling interest

-594

-485

-445

-191

-69

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4

2

Net loss attributable to Inovio Pharmaceuticals, Inc.

-32,541

-37,662

-23,090

-29,387

-29,219

-32,962

-25,015

-6,639

-32,350

-

-

-

-

-26,233

-20,759

-18,704

-8,042

-17,952

5,594

-6,248

-10,581

-7,411

-7,177

-10,711

-10,821

-15,454

-30,877

-10,852

-8,844

-658

-6,622

-4,133

-8,254

-5,476

-4,541

-2,822

-2,412

-1,410

-7,616

Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders
Basic and diluted (in dollars per share)

-0.26

-

-

-

-0.30

-

-

-

-0.36

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

-0.05

-0.03

-0.06

-0.04

-0.04

-0.02

-0.02

-0.01

-0.07

Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders
Basic ($ per share)

-

-0.38

-0.23

-0.30

-

-0.34

-0.27

-0.07

-

-0.24

-0.39

-0.13

-0.31

-0.35

-0.28

-0.26

-0.11

-0.25

0.08

-0.09

-0.17

-0.12

-0.12

-0.18

-0.20

-0.30

-0.64

-0.24

-0.23

-

-

-

-

-

-

-

-

-

-

Diluted ($ per share)

-

-0.38

-0.25

-0.30

-

-0.34

-0.27

-0.08

-

-0.24

-0.40

-0.13

-0.31

-0.36

-0.28

-0.26

-0.11

-0.25

0.07

-0.09

-0.18

-0.12

-0.12

-0.19

-0.20

-0.30

-0.64

-0.24

-0.23

-

-

-

-

-

-

-

-

-

-

Weighted average number of common shares outstanding
Weighted average number of common shares outstanding
Basic (shares)

-

-

-

-

-

-

92,423

91,153

-

-

-

-

-

-

-

-

-

-

-

-

-

60,610

60,392

60,232

55,159

52,127

47,989

44,988

39,038

-

-

-

-

-

-

-

-

-

-

Diluted (shares)

-

-

-

-

-

-

92,423

91,241

-

-

-

-

-

-

-

-

-

-

-

-

-

60,805

60,602

60,474

55,159

52,127

47,989

44,988

39,038

-

-

-

-

-

-

-

-

-

-

Basic and diluted (in shares)

124,623

-

-

-

97,494

-

-

-

90,451

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

140,704

135,389

134,968

134,968

129,382

127,256

127,256

120,922

-

-

Weighted average number of common shares outstanding - basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

102,928

102,811

Revenue under collaborative research and development arrangements
Revenue from Contract with Customer, Excluding Assessed Tax

71

184

617

64

2,770

2,372

1,813

24,385

1,289

7,409

351

16,358

4,288

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue under collaborative research and development arrangements with affiliated entities
Revenue from Contract with Customer, Excluding Assessed Tax

1,172

55

53

71

55

56

184

60

148

226

129

176

233

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Miscellaneous revenue, including from affiliated entities
Revenue from Contract with Customer, Excluding Assessed Tax

-

-

-

-

-

73

-

-

-

980

1,456

2,797

5,240

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grants and miscellaneous revenue from affiliated entity
Revenue from Contract with Customer, Excluding Assessed Tax

-

-

-

-

-

-

-

-

-

171

707

1,079

614

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Miscellaneous revenue
Revenue from Contract with Customer, Excluding Assessed Tax

83

-

196

0

3

-

2

2

92

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-